Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

Cell

Volumn 116, Issue 6, 2004, Pages 855-867

  Wan, Paul T C ^a   Garnett, Mathew J ^a   Roe, S Mark ^a   Lee, Sharlene ^a   Niculescu Duvaz, Dan ^a   Good, Valerie M ^a   Project, Cancer Genome ^b   Jones, C Michael ^a   Marshall, Christopher J ^a   Springer, Caroline J ^a   Barford, David ^a   Marais, Richard ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN INHIBITOR; RAF PROTEIN;

ANIMAL CELL; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE MUTATION; IN VIVO CULTURE; MOLECULAR MECHANICS; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; WILD TYPE;

ALLOSTERIC REGULATION; ANIMALS; CATALYTIC DOMAIN; CELL TRANSFORMATION, NEOPLASTIC; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; MAP KINASE KINASE 1; MAP KINASE SIGNALING SYSTEM; MICE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MITOGEN-ACTIVATED PROTEIN KINASES; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MUTATION; NEOPLASMS; NIH 3T3 CELLS; ONCOGENES; OOCYTES; PHOSPHORYLATION; PHOSPHOTRANSFERASES; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-RAF; UP-REGULATION; XENOPUS;

ANIMALIA;

EID: 12144289677     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0092-8674(04)00215-6     Document Type: Article

References (48)

1. Avruch J., Khokhlatchev A., Kyriakis J.M., Luo Z., Tzivion G., Vavvas D., Zhang X.F. Ras activation of the Raf kinase. tyrosine kinase recruitment of the MAP kinase cascade Recent Prog. Horm. Res. 56:2001;127-155.
2. Azam M., Latek R.R., Daley G.Q. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell. 112:2003;831-843.
3. Bankston D., Dumas J., Natero R., Reidl B., Monahan M.K., Sibley R. A scaleable Synthesis of BAY 43-9006. A potent raf kinase inhibitor for the treatment of cancer Organic Process Res. & Dev. 6:2002;777-781.
4. Blagosklonny M.V. Hsp-90-associated oncoproteins. multiple targets of geldanamycin and its analogs Leukemia. 16:2002;455-462.
5. Brose M.S., Volpe P., Feldman M., Kumar M., Rishi I., Gerrero R., Einhorn E., Herlyn M., Minna J., Nicholson A.et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 62:2002;6997-7000.
6. Brunger A.T., Adams P.D., Clore G.M., DeLano W.L., Gros P., Grosse-Kunstleve R.W., Jiang J.S., Kuszewski J., Nilges M., Pannu N.S.et al. Crystallography & NMR system. A new software suite for macromolecular structure determination Acta Crystallogr. D Biol. Crystallogr. 54:1998;905-921.
7. CCP4 The CCP4 (Collaborative Computational Project Number 4) Suite. programs for protein crystallography Acta Cryst D. 50:1991;760-763.
8. Chong H., Lee J., Guan K.L. Positive and negative regulation of Raf kinase activity and function by phosphorylation. EMBO J. 20:2001;3716-3727.
9. Cohen Y., Goldenberg-Cohen N., Parrella P., Chowers I., Merbs S.L., Pe'er J., Sidransky D. Lack of BRAF mutation in primary uveal melanoma. Invest. Ophthalmol. Vis. Sci. 44:2003;2876-2878.
10. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W.et al. Mutations of the BRAF gene in human cancer. Nature. 417:2002;949-954.
11. Dent J.A., Polson A.G., Klymkowsky M.W. A whole-mount immunocytochemical analysis of the expression of the intermediate filament protein vimentin in Xenopus. Development. 105:1989;61-74.
12. Fabian J.R., Daar I.O., Morrison D.K. Critical tyrosine residues regulate the enzymatic and biological activity of Raf-1 kinase. Mol. Cell. Biol. 13:1993;7170-7179.
13. Farrar M.A., Alberol-Ila, Perlmutter R.M. Activation of the Raf-1 kinase cascade by coumermycin-induced dimerization. Nature. 383:1996;178-181.
14. Glover H.R., Baker D.A., Celetti A., Dibb N.J. Election of activating mutations of c-fms in FDC-P1 cells. Oncogene. 11:1995;1347-1356.
15. Grant B.D., Hemmer W., Tsigelny I., Adams J.A., Taylor S.S. Kinetic analyses of mutations in the glycine-rich loop of cAMP-dependent protein kinase. Biochemistry. 37:1998;7708-7715.
16. Hubbard S.R., Wei L., Ellis L., Hendrickson W.A. Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature. 372:1994;746-754.
17. Ikenoue T., Hikiba Y., Kanai F., Tanaka Y., Imamura J., Imamura T., Ohta M., Ijichi H., Tateishi K., Kawakami T.et al. Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors. Cancer Res. 63:2003;8132-8137.
18. Johnson L.N., Noble M.E., Owen D. Active and inactive protein kinases. structural basis for regulation Cell. 85:1996;149-158.
19. Jones T.A., Zou J.Y., Cowan S.W., Kjeldgaard M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A. 47:1991;110-119.
20. Jones C.M., Dale L., Hogan B.L., Wright C.V., Smith J.C. Bone morphogenetic protein-4 (BMP-4) acts during gastrula stages to cause ventralization of Xenopus embryos. Development. 122:1996;1545-1554.
21. Kitayama H., Kanakura Y., Furitsu T., Tsujimura T., Oritani K., Ikeda H., Sugahara H., Mitsui H., Kanayama Y., Kitamura Y.et al. Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines. Blood. 85:1995;790-798.
22. Kolch W. Meaningful relationships. the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions Biochem. J. 351:2000;289-305.
23. Lowinger T.B., Riedl B., Dumas J., Smith R.A. Design and discovery of small molecules targeting raf-1 kinase. Curr. Pharm. Des. 8:2002;2269-2278.
24. Luo Z., Tzivion G., Belshaw P.J., Vavvas D., Marshall M., Avruch J. Oligomerization activates c-Raf-1 through a Ras-dependent mechanism. Nature. 383:1996;181-185.
25. Lyons J.F., Wilhelm S., Hibner B., Bollag G. Discovery of a novel Raf kinase inhibitor. Endocr. Relat. Cancer. 8:2001;219-225.
26. MacNicol M.C., Muslin A.J., MacNicol A.M. Disruption of the 14-3-3 binding site within the B-Raf kinase domain uncouples catalytic activity from PC12 cell differentiation. J. Biol. Chem. 275:2000;3803-3809.
27. Malumbres M., Barbacid M. RAS oncogenes. the first 30 years Nat. Rev. Cancer. 3:2003;459-465.
28. Manning G., Whyte D.B., Martinez R., Hunter T., Sudarsanam S. The protein kinase complement of the human genome. Science. 298:2002;1912-1934.
29. Marais R., Light Y., Paterson H.F., Mason C.S., Marshall C.J. Differential regulation of Raf-1, A-Raf and B-Raf by oncogenic Ras and tyrosine kinases. J. Biol. Chem. 272:1997;4378-4383.
30. Marais R., Light Y., Mason C., Paterson H., Olson M., Marshall C.J. Requirement of Ras-GTP-Raf complexes for activation of Raf-1 by protein kinase C. Science. 280:1998;109-112.
31. Mason C.S., Springer C., Cooper R.G., Superti-Furga G., Marshall C.J., Marais R. Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation. EMBO J. 18:1999;2137-2148.
32. Michaud N.R., Fabian J.R., Mathes K.D., Morrison D.K. 14-3-3 is not essential for Raf-1 function. identification of Raf-1 proteins that are biologically activated in a 14-3-3- and Ras-independent manner Mol. Cell. Biol. 15:1995;3390-3397.
33. Morrison D.K. Ksr. a mapk scaffold of the ras pathway? J. Cell Sci. 114:2001;1609-1612.
34. Morrison D.K., Cutler R.E.J. The complexity of Raf-1 regulation. Curr. Opin. Cell Biol. 9:1997;174-179.
35. Nagar B., Bornmann W.G., Pellicena P., Schindler T., Veach D.R., Miller W.T., Clarkson B., Kuriyan J. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 62:2002;4236-4243.
36. Nieuwkoop P., Faber J. Normal Table of Xenopus laevis. 1967;Daudin, Amsterdam.
37. Pargellis C., Tong L., Churchill L., Cirillo P.F., Gilmore T., Graham A.G., Grob P.M., Hickey E.R., Moss N., Pav S., Regan J. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat. Struct. Biol. 9:2002;268-272.
38. Rajagopalan H., Bardelli A., Lengauer C., Kinzler K.W., Vogelstein B., Velculescu V.E. Tumorigenesis. RAF/RAS oncogenes and mismatch-repair status Nature. 418:2002;934.
39. Rapp U.R., Goldsborough M.D., Mark G.E., Bonner T.I., Groffen J., Reynolds F.H., Stephenson J.R. Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus. Proc. Natl. Acad. Sci. USA. 80:1983;4218-4222.
40. Reidl, B., Dumas, J., Khire, U., Lowinger, T.B., Scott, W.J., Smith, R.A., Wood, J.E., Monahan, M.K., Natero, R., Renick, J., and Sibley, R. (2000). Preparation of w-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors. In PCT Int. Appl. WO 200041698.
41. Robinson M.J., Cobb M.H. Mitogen-activated protein kinase pathways. Curr. Opin. Cell Biol. 9:1997;180-186.
42. Schindler T., Bornmann W., Pellicena P., Miller W.T., Clarkson B., Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science. 289:2000;1938-1942.
43. Singer G., Oldt R. 3rd, Cohen Y., Wang B.G., Sidransky D., Kurman R.J., Shih I. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J. Natl. Cancer Inst. 95:2003;484-486.
44. Stancato L.F., Chow Y.H., Hutchison K.A., Perdew G.H., Jove R., Pratt W.B. Raf exists in a native heterocomplex with hsp90 and p50 that can be reconstituted in a cell-free system. J. Biol. Chem. 268:1993;21711-21716.
45. Weber C.K., Slupsky J.R., Kalmes H.A., Rapp U.R. Active Ras induces heterodimerization of cRaf and BRaf. Cancer Res. 61:2001;3595-3598.
46. Yang J., Cron P., Good V.M., Thompson V., Hemmings B.A., Barford D. Crystal structure of an activated Akt/protein kinase B ternary complex with GSK3-peptide and AMP-PNP. Nat. Struct. Biol. 9:2002;940-944.
47. Yuen S.T., Davies H., Chan T.L., Ho J.W., Bignell G.R., Cox C., Stephens P., Edkins S., Tsui W.W., Chan A.S.et al. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res. 62:2002;6451-6455.
48. Zhang B.H., Guan K.L. Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601. EMBO J. 19:2000;5429-5439.